The National Association of Boards of Pharmacy is backing a plan to give the FDA power over large compounding pharmacies with the goal of preventing outbreaks caused by contaminated treatments. "We welcome the clarifications provided by the proposed legislation to the regulatory uncertainties that currently exist and were one of the primary factors leading to the meningitis tragedy," NABP Director Dr. Carmen Catizone told a hearing of the Senate health panel in Washington.

Related Summaries